683 Capital Management’s Amicus Therapeutics FOLD Stock Holding History

683 Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Sell	775,000 -25,000	-3%	-$358K	0.58%	38
2025 Q4	$11.4M	Sell	800,000 -35,000	-4%	-$344K	0.5%	43
2025 Q3	$6.58M	Sell	835,000 -125,000	-13%	-$890K	0.34%	60
2025 Q2	$5.5M	Buy	960,000 +685,000	+249%	+$4.42M	0.36%	71
2025 Q1	$2.24M	Buy	+275,000	New	+$2.54M	0.15%	106

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

683 Capital Management's FOLD Position: Q1 2026 in Review

683 Capital Management reduced its Amicus Therapeutics (FOLD) stake by 3.1% in Q1 2026, selling an estimated $358K and leaving 775,000 shares worth $11.2M. The position accounts for 0.58% of the portfolio, ranked #38.

683 Capital Management first reported a position in FOLD in Q1 2025 and has held it in 5 quarters since. The position peaked at $11.4M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

683 Capital Management held 775,000 shares of Amicus Therapeutics worth $11.2M as of Q1 2026.
683 Capital Management sold 25,000 Amicus Therapeutics shares in Q1 2026, an estimated $358K.
Amicus Therapeutics made up 0.58% of 683 Capital Management's portfolio in Q1 2026, its #38 holding.
683 Capital Management first reported a position in Amicus Therapeutics in Q1 2025 and has held it in 5 quarters since.
683 Capital Management's Amicus Therapeutics position peaked at $11.4M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.